<!DOCTYPE html>
<html lang="en">
  <head>
  <title>Galaxy Europe | New Paper "Transcriptome profiling of cisplatin resistance in triple-negative breast cancer: New insight into the role of PI3k/Akt pathway"</title>
  <meta property="og:title" content="New Paper "Transcriptome profiling of cisplatin resistanc..." />
  <meta property="og:description" content="Amir Sabbaghian and colleagues have published a paper rel..." />
  <meta property="og:image" content="/assets/media/galaxy-eu-logo.512.png" />
  <meta name="description" content="The European Galaxy Instance">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">

  <link rel="stylesheet" href="/assets/css/bootstrap.min.css">
  <link rel="stylesheet" href="/assets/css/main.css">




  <link rel="canonical" href="https://galaxyproject.eu/posts/2022/05/27/paper-tnbc/plain.html">
  <link rel="shortcut icon" href="/assets/media/galaxy-eu-logo.64.png" type="image/x-icon" />
  <link rel="alternate" type="application/rss+xml" title="Galaxy Europe" href="/feed.xml">

  <link href="/assets/css/font-awesome.min.css" rel="stylesheet" integrity="sha384-wvfXpqpZZVQGK6TAh5PVlGOfQNHSoD2xbE+QkPxCAFlNEevoEH3Sl0sibVcOQVnN" crossorigin="anonymous">
  <script src="/assets/js/jquery-3.2.1.slim.min.js" integrity="sha256-k2WSCIexGzOj3Euiig+TlR8gA0EmPjuc79OEeY5L45g=" crossorigin="anonymous"></script>
  <script src="/assets/js/bootstrap.min.js" integrity="sha256-U5ZEeKfGNOja007MMD3YBI0A3OSZOQbeG6z2f2Y0hu8=" crossorigin="anonymous"></script>
</head>

  <body>
    <div id="wrap">
      <div id="main">
        <div class="container" id="maincontainer">
          




<section id="news-page">
  <div class="row news-header-row">
    
    <a class="col-xs-1 text-center" href="/posts/2022/05/23/tool-update/plain.html">
      «
    </a>
    
    <div class="col-xs-10 ">
      <div class="text-center">
        <h2 class="title">New Paper &quot;Transcriptome profiling of cisplatin resistance in triple-negative breast cancer: New insight into the role of PI3k/Akt pathway&quot;</h2>
      </div>
      <hr />
    </div>
    
    <a class="col-xs-1 text-center" href="/posts/2022/05/29/tool-update/plain.html">
      »
    </a>
    
  </div>
  <div class="row post-metadata">
    <div class="col-md-8 col-md-offset-2">
      <div class="row">
        <div class="col-md-6">
            

        </div>
        <div class="col-md-6 text-right">
          <div>
            <span class="post-date">
              May 27, 2022
            </span>

            

            <br />
            <span class="post-tags">
                <span class="label label-success"></span>
              
                <span class="label label-info">paper</span>
              
                <span class="label label-info">citations</span>
              
              
                <a href="https://dx.doi.org/10.2174/1566524022666220517102423">
                <span class="label label-warning">DOI:10.2174/1566524022666220517102423</span>
                </a>
              
            </span>

            
          </div>
        </div>
      </div>
    </div>
  </div>

  <div class="row">
    <div class="col-md-8 col-md-offset-2">
      <div class="news-content">
        <p>Amir Sabbaghian and colleagues have published a paper related to the resistance to cisplatin in the treatment of triple negative breast cancer. Thanks for using the European Galaxy server and sharing your results with us!</p>

<p><strong>Background:</strong> Aggressive nature of triple negative breast cancer (TNBC) is associated with poor prognosis compared with other breast cancer types. Current guidelines recommend the use of Cisplatin for the management of TNBC. However, the development of resistance to cisplatin is the primary cause of chemotherapy failure.</p>

<p><strong>Objective:</strong> In the present study, we aimed to develop a stable cisplatin-resistant TNBC cell line to investigate the key pathways and genes involved in cisplatin-resistant TNBC.</p>

<p><strong>Methods:</strong> The MDA-MB-231 cell was exposed to different concentrations of cisplatin. After 33 generations, cells showed a resistant phenotype. Then, RNA-sequencing analysis was performed in cisplatin-resistant and parent cell lines. The RNA-sequencing data was verified by quantitative PCR (qPCR).</p>

<p><strong>Results:</strong> The IC50 of the resistant cell increased to 10-fold of parental cell (p&lt;0.001). Also, cisplatin-resistant cells show cross-resistance to other drugs, including 5-fluorouracil, paclitaxel, and doxorubicin. Resistant cells demonstrated reduced drug accumulation compared to the parental cells. Results showed there were 116 differentially expression genes (DEGs) (p&lt;0.01). Gene ontology analysis revealed that the DEGs have several molecular functions, including binding and transporter activity. Functional annotation showed that the DEGs were enriched in the drug resistance-related pathways, especially the PI3K-Akt signaling pathway. The most important genes identified in the protein-protein interaction network were heme oxygenase 1 (HMOX1) and TIMP metallopeptidase inhibitor 3 (TIMP3).</p>

<p><strong>Conclusion</strong>: We have identified several pathways and DEGs associated with the PI3K-Akt pathway, which provides new insights into the mechanism of cisplatin resistance, and potential drug targets in TNBC.</p>

      </div>
    </div>
  </div>



</section>

        </div>
      </div>
    </div>
    







<footer class="navbar-default">
    <div class="container">
        <div class="row">
        </div>
        <div class="row">
            <div class="col-lg-12" style="text-align:center">
                <p>UseGalaxy.eu is maintained largely by the <a href="/freiburg/">Freiburg Galaxy Team</a> but also collectively by groups and individuals from across Europe. All of the member sites in this repository contribute to the European Galaxy Project.
For <strong>acknowledgement</strong>, please refer to the <a href="/about">About</a> section.
All content on this site is available under <a href="https://creativecommons.org/share-your-work/public-domain/cc0/">CC0-1.0</a> unless otherwise specified.</p>

            </div>
        </div>
        <div class="row">
            <div class="col-lg-12" style="text-align:center">
                <ul class="contact-info">
                    <li><i class="fa fa-github"></i><a href="https://github.com/usegalaxy-eu/website/tree/master/_posts_plain/2022-05-27-paper-tnbc.md" target="_blank">Edit this page on GitHub</a></li>
                    
                      <li><i class="fa fa-envelope"></i><a href="mailto:contact@usegalaxy.eu">contact@usegalaxy.eu</a></li>
                    
                    
                      <li><i class="fa fa-github"></i><a href="https://github.com/usegalaxy-eu" target="_blank">usegalaxy-eu</a></li>
                    
                    
                    
                      <li><img class="fa-mastodon" src="/assets/media/mastodon.svg" style="width:18px;height:18px;padding-right:4px;filter:grayscale(100%);-webkit-filter:grayscale(100%);"/><a href="https://bawü.social/@galaxyfreiburg" target="_blank">galaxyfreiburg</a></li>
                    
                      <li><i class="fa fa-rss"></i>Subscribe <a href="/feed.xml">via RSS (UseGalaxy.eu Feed)</a></li>
                </ul>
            </div>
        </div>
    </div>
</footer>

<script async defer data-domain="galaxyproject.eu" src="https://plausible.galaxyproject.eu/js/plausible.js"></script>
  </body>
</html>
